{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:10:02Z","timestamp":1784225402844,"version":"3.55.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Three hexavalent (DTaP-IPV-Hib-HepB) vaccines are licensed in Europe, only one of which (Vaxelis, Hex-V), uses a meningococcal outer membrane protein complex as a carrier protein for\n                      <jats:italic toggle=\"yes\">Hemophilus influenza<\/jats:italic>\n                      type b (Hib), creating potential interactions with the meningococcal vaccine 4CMenB.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this single-center open-label randomized trial, infants were randomized in a 1:1 ratio to receive Hex-V or an alternative hexavalent vaccine (Infanrix-Hexa, Hex-IH) at 2, 3, and 4 months with 4CMenB (2, 4, and 12 months) in the UK routine immunization schedule. The primary outcome was noninferiority of geometric mean concentrations (GMCs) of anti-PRP (Hib) IgG at 5 months of age. Secondary outcomes included safety, reactogenicity, and immunogenicity of other administered vaccines measured at 5 and 13 months of age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 194 participants enrolled, 96 received Hex-V and 98 Hex-IH. Noninferiority of anti-PRP IgG GMCs at 5 months of age in participants receiving Hex-V was established; GMCs were 23-times higher following three doses of Hex-V than three doses of Hex-IH (geometric mean ratio (GMR) 23.25; one-sided 95% CI 16.21, -). 78\/85 (92%) of Hex-V recipients and 43\/87 (49%) of Hex-IH recipients had anti-PRP antibodies \u22651.0 \u00b5g\/mL. At 5 months of age serum, bactericidal activity titers against MenB strain 5\/99 were higher following Hex-V than Hex-IH (GMR 1.56; 95% CI, 1.13\u20132.14). The reactogenicity profile was similar in both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These data support flexibility in the use of either Hex-IH or Hex-V in infant immunization schedules containing 4CMenB, with the possibility that Hex-V may enhance protection against Hib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000003753","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T11:03:24Z","timestamp":1670411004000},"page":"66-73","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["A Randomized Trial Assessing the Immunogenicity and Reactogenicity of Two Hexavalent Infant Vaccines Concomitantly Administered With Group B Meningococcal Vaccine"],"prefix":"10.1097","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1349-0526","authenticated-orcid":false,"given":"Matthew","family":"Rajan","sequence":"first","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Marchevsky","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Jefferies","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Owino","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam","family":"Hallis","sequence":"additional","affiliation":[{"name":"UK Health Security Agency, Porton Down, Salisbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldblatt","sequence":"additional","affiliation":[{"name":"Immunobiology Section, University College London, Great Ormond Street Institute of Child Health Biomedical Research Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Matheson","sequence":"additional","affiliation":[{"name":"National Infection Service, Public Health England, Porton, Salisbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Cuthbertson","sequence":"additional","affiliation":[{"name":"National Infection Service, Public Health England, Porton, Salisbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvinder","family":"Aley","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxue","family":"Liu","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Snape","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK"},{"name":"National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"key":"R1-20260716","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/archdischild-2019-318047","article-title":"Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience.","volume":"105","author":"Isitt","year":"2020","journal-title":"Arch Dis Child"},{"key":"R3-20260716","doi-asserted-by":"crossref","first-page":"e02695326953","DOI":"10.1136\/bmjopen-2018-026953","article-title":"Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials.","volume":"9","author":"Zafack","year":"2019","journal-title":"BMJ Open"},{"key":"R4-20260716","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1016\/j.vaccine.2016.05.054","article-title":"A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11\u201312 months.","volume":"34","author":"Silfverdal","year":"2016","journal-title":"Vaccine"},{"key":"R5-20260716","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/INF.0000000000001406","article-title":"A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at two, three, four and twelve months.","volume":"36","author":"Vesikari","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R6-20260716","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4161\/hv.26269","article-title":"Human vaccines & immunotherapeutics combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-haemophilus influenzaee type b vaccine; InfanrixTM Hexa twelve years of experience in Italy.","volume":"10","author":"Baldo","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R7-20260716","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40272-016-0208-y","article-title":"DtaP5-HB-IPV-Hib vaccine (Vaxelis \u00d2): a review of its use in primary and booster vaccination.","volume":"19","author":"Syed","year":"2016","journal-title":"Pediatric Drugs"},{"key":"R8-20260716","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3201\/eid1206.051451","article-title":"Haemophilus influenzaee type b reemergence after combination immunization.","volume":"12","author":"Johnson","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"R10-20260716","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/cid\/civ695","article-title":"Antibody responses after primary immunization in infants born to women receiving a Pertussis-containing vaccine during pregnancy: Single arm observational study with a historical comparator.","volume":"61","author":"Ladhani","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R11-20260716","first-page":"970","article-title":"Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine.","volume":"12","author":"Borrow","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"R12-20260716","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays.","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"R13-20260716","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1128\/CVI.05252-11","article-title":"Establishment of a new human pneumococcal standard reference serum, 007sp.","volume":"18","author":"Goldblatt","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"R16-20260716","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1016\/j.vaccine.2010.02.103","article-title":"Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies.","volume":"28","author":"Jegerlehner","year":"2010","journal-title":"Vaccine"},{"key":"R17-20260716","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.vaccine.2014.11.026","article-title":"Carrier priming with CRM197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: Biophysical and immunochemical interpretation.","volume":"33","author":"Pecetta","year":"2015","journal-title":"Vaccine"},{"key":"R21-20260716","first-page":"385","article-title":"Pertussis vaccines: WHO position paper.","volume":"85","year":"2010","journal-title":"Releve epidemiologique hebdomadaire"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:02:12Z","timestamp":1784224932000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003753","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}